RecruitingNCT07163728

Leptin: A Marker for AML Chemo-Sensitivity

Bone Marrow Supernatant Leptin as A Predictor of Chemotherapy Sensitivity in AML Patients

Sponsor

Fujian Medical University Union Hospital

Enrollment

86 participants

Start Date

Aug 1, 2025

Study Type

OBSERVATIONAL

Conditions

AML Adult

Summary

Acute Myeloid Leukemia (AML) is a malignant clonal disorder of hematopoietic stem/progenitor cells, with a five-year survival rate of approximately 30%. Chemotherapy resistance and relapse remain major challenges. Increased bone marrow adipocytes contribute to AML cell drug resistance.This study found that elevated levels of the adipokine leptin enhance oxidative phosphorylation (OXPHOS) in AML cells, accompanied by increased mitochondrial reactive oxygen species (mtROS), which stimulates antioxidant capacity and thereby induces chemotherapy resistance. By establishing a correlation between leptin levels in bone marrow supernatant and clinical outcomes in AML patients, this research provides novel strategic insights for targeting drug resistance and improving prognostic evaluation.

Eligibility

Min Age: 18 Years

Inclusion Criteria3

Clinical diagnosis aligns with the "Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2023)";
All patients are experiencing their first onset of the disease and have not received any related chemotherapy prior to the study;
Patients participate in the study accompanied by family members and sign informed consent documents.

Exclusion Criteria6

Patients with concurrent malignancies requiring treatment;
Presence of infectious diseases, including SARS, viral hepatitis, or HIV/ AIDS;
Major surgery performed within the last 21 days;
Performance Status (PS) score >3;
Severe liver or kidney dysfunction or serious infection;
Severe psychiatric conditions that impair understanding of the study protocol or voluntary withdrawal.